Kulkarni Samarth 4
4 · CRISPR Therapeutics AG · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
CRISPR (CRSP) CEO Samarth Kulkarni Sells 9,798 Shares
What Happened
Samarth Kulkarni, CEO of CRISPR Therapeutics (CRSP), reported conversion/exercise of 19,250 derivative/RSU units into common shares on March 10, 2026, and an open-market sale of 9,798 shares on March 11, 2026 at $52.80 each, generating $517,334. The filing shows the sale was made to satisfy tax withholding obligations tied to RSU vesting and was not a discretionary trade.
Key Details
- Transaction dates and prices:
- 2026-03-10: Exercise/conversion of 19,250 derivative/RSU units into common shares (code M).
- 2026-03-11: Open-market sale of 9,798 shares at $52.80 per share, proceeds $517,334 (code S).
- Shares owned after transaction: not specified in the filing.
- Notable footnotes:
- F1: Some shares remain subject to a lock-up agreement with the underwriters of the issuer’s convertible notes offering.
- F2–F4: These were restricted stock units (RSUs) granted 3/10/2023 for 77,000 shares with quarterly vesting; the reported activity relates to the vesting of the March 10, 2026 tranche.
- F3: The 9,798-share sale was mandated by the company’s RSU Settlement Policy to cover tax withholding — it is not a discretionary sale.
- Filing timeliness: filing dated 2026-03-12 for transactions on 3/10–3/11; no indication in the filing that it was late.
Context
- This activity reflects standard RSU settlement mechanics: a tranche vested and converted to shares, and a portion was sold to cover taxes. Such mandated, non-discretionary sales are common after RSU vesting and do not necessarily signal the insider’s view on the stock.
Insider Transaction Report
Form 4
Kulkarni Samarth
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Shares
[F1][F2]2026-03-10+19,250→ 245,356 total - Sale
Common Shares
[F3]2026-03-11$52.80/sh−9,798$517,334→ 235,558 total - Exercise/Conversion
Restricted Stock Units
[F2][F1][F4]2026-03-10−19,250→ 19,250 total→ Common Shares (19,250 underlying)
Footnotes (4)
- [F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
- [F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F4]This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027.
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact|2026-03-12